Cancer has an etiology that involves a wide range of genetic interactions and dysfunction across multiple systems. These characteristics make cancer one of the most scientifically complex diseases, making design of oncology clinical trials, especially early-stage studies, challenging. With the emergence of precision medicine, there has been a shift in how early-phase oncology trials are conducted, including a growing number of Phase 1 trials reporting preliminary response rates. This white paper addresses clinical trials in precision medicine and explores the expanding role of adaptive trial designs in Phase 1 and Phase 2 oncology studies. Download the full whitepaper here.
You are here: / / Minimizing Risk & Accelerating Timelines in Oncology Trials